Do you look signs and symptoms of EIMs when evaluating your IBD patients?
What are the most common EIM’s you see?
How might the overlap of the these diseases impact how you approach chronic inflammatory decisions in GI?
How do you determine what is driving the disease with the overlap of immune mediated diseases?
Given the systemic nature of these diseases, how would this impact your approach to treating your patients with IBD?
Start: August 18 2017, 6:00 am
End: August 18 2017, 9:30 pm
Cost: IBDH Sponsored
Credits: Closed Session invitation only
06:00 – Welcome to case Studies
06:15 – Clinical challenge: 28 year old Female with Crohn’s enterocolitis and active symptoms, wants to get pregnant soon and apprehensive of starting biologic treatment. Discuss safety profile of biologics and risk for placental transfer.
07:15 Clinical challenge: 43 year old with Crohn’s disease on weekly Humira, with loss of response, low trough level and elevated antibody: what is next?
08:15 – Clinical challenge: 37 year old on Humira, insurance provider requesting switch to biosimilar, how to approach
09:00 – Open discussion on future needs of IBD education